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Background: OTUB1 (OTU deubiquitinase, ubiquitin aldehyde binding 1) is a deubiquitinating enzyme (DUB) that
belongs to the OTU (ovarian tumor) superfamily. The aim of this study was to clarify the role of OTUB1 in colorectal
cancer (CRC) and to identify the mechanism underlying its function.
Methods: Two hundred and sixty CRC samples were subjected to association analysis of OTUB1 expression and
clinicopathological variables using immunohistochemical (IHC) staining. Overexpression of OTUB1 was achieved in
SW480 and DLD-1 cells, and downregulation of OTUB1 was employed in SW620 cells. Then, migration and invasion
assays were performed, and markers of the epithelial-mesenchymal transition (EMT) were analyzed. In addition,
hepatic metastasis models in mice were used to validate the function of OTUB1 in vivo.
Results: OTUB1 was overexpressed in CRC tissues, and the expression level of OTUB1 was associated with
metastasis. A high expression level of OTUB1 was also associated with poor survival, and OTUB1 served as an
independent prognostic factor in multivariate analysis. OTUB1 also promoted the metastasis of CRC cell lines
in vitro and in vivo by regulating EMT.
Conclusions: OTUB1 promotes CRC metastasis by facilitating EMT and acts as a potential distant metastasis
marker and prognostic factor in CRC. Targeting OTUB1 may be helpful for the treatment of CRC.
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Colorectal cancer (CRC) represents a leading cause of
cancer mortality worldwide. In the United States, CRC is
the third most common cancer among both men and
women and was the third leading cause of cancer death
in 2012. The five-year survival rates for colon cancer
and rectal cancer are 65% and 68%, respectively [1]. The
leading cause of death in patients with CRC is liver me-
tastasis; approximately 14-25% of patients with CRC present
with liver metastasis at diagnosis, and more patients will de-
velop metastasis after diagnosis [2-4]. Therefore, exploring
the molecular makers of metastasis and elucidating the
underlying metastatic mechanisms are very important for* Correspondence: changchuanpan@126.com; hwenl@mail.sysu.edu.cn
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evaluation of patients with CRC.
Deubiquitinating enzymes (DUBs) comprise a large
group of proteases that can cleave monoubiquitin or
polyubiquitin from target proteins. Many DUBs, such as
USP46, USP22, UCHL1, and USP9X, have been shown
to play important roles in the proliferation, metastasis,
and drug resistance of CRC [5-8]. OTUB1 (OUT deubi-
quitinase, ubiquitin aldehyde binding 1) belongs to the
ovarian tumor domain protease (OTU) family of DUBs
[9]. OTUB1 is a cysteine protease that hydrolyses the
isopeptide bond between ubiquitin and the target mol-
ecule. By recognizing a Lys48-linked ubiquitin chain and
inhibiting ubiquitin transfer by binding to UBC13, UBE2D,
and UBE2E family E2 enzymes, OTUB1 specifically cleaves
Lys48-linked polyubiquitin chains [10-12]. Furthermore,
OTUB1 has been reported to inhibit the Lys63-linked
polyubiquitin of DNA double-strand breaks by targetinghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathological findings and correlation with
OTUB1 expression
Variables No. (%) OTUB1 low OTUB1 high P value
Total cases 260 123 (47.3) 137 (52.7)
Age (years)
<65 171 (65.8) 79 (30.4) 92 (35.4) 0.62
≥65 89 (34.2) 44 (16.9 ) 45 (17.3)
Gender
Male 140 (53.8) 63 (24.2) 77 (29.6) 0.421
Female 120 (46.2) 60 (23.1) 60 (23.1)
Tumor location
Colon 134 (51.5) 57 (21.9) 77 (29.6) 0.112
Rectum 126 (48.5) 66 (25.4) 60 (23.1)
Tumor size (cm)
<5 117 (45.0) 62 (23.8) 55 (21.2) 0.097
≥5 143 (55.0) 61 (23.5) 82 (31.5)
Tumor invasive
depth†
T1-T2 64 (24.6) 42 (16.1) 22 (8.5) 0.001*
T3-T4 196 (75.4) 81 (31.2) 115 (44.2)
Lymph node status
<1 140 (53.8) 76 (29.2) 64 (24.6) 0.015*
≥1 120 (46.2) 47 (18.1) 73 (28.1)
Distant metastasis
No metastasis 200 (76.9) 103 (39.6) 97 (37.3) 0.013*
metastasis 60 (23.1) 20 (7.7) 40 (15.4)
AJCC/TNM stage
I 61 (23.5) 40 (15.4) 21 (8.1) 0.003*
II 63 (24.2) 30 (11.5) 33 (12.7)
III 76 (29.2) 34 (13.1) 42 (16.1)
IV 60 (23.1) 19 (7.3) 41 (15.8)
Chemotherapy
Yes 141 (54.2) 59 (22.7) 82 (31.5) 0.055
No 119 (45.8) 64 (24.6) 55 (21.2)
Preoperative
CEA (ng/mL)‡
<=5 136 (55.3) 71 (28.9) 65 (26.4) 0.181
>5 110 (44.7) 48 (19.5) 62 (25.2)
†According to the 7th Edition of the AJCC Cancer Staging Manual.
‡Analysis for this parameter was available in 246 cases.
*Statistically significant, P <0.05.
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regulation of physiological and pathological processes.
For example, OTUB1 regulates T cell anergy via GRAIL
[16], and in TGFβ induction, OTUB1 inhibits the ubiqui-
tylation of phospho-SMAD2/3 [17]. OTUB1 also stabilizes
c-IAP1 expression and promotes TWEAK-induced activa-
tion of the NF-κB and MAPK signaling pathways [18].
P53 is a gatekeeper of cell growth and division, and the
important function of OTUB1 is the direct suppression of
MDM2-mediated p53 ubiquitination to stabilize and acti-
vate p53 [19]. Deletions and mutations of the p53 gene
can be detected in 65% to 85% of colorectal tumors
[20,21]. In this study, we investigated the association be-
tween OTUB1 expression and survival in CRC and sought
to elucidate the molecular mechanisms governing the role
of OTUB1 in promoting CRC metastasis.
Results
Association between OTUB1 expression and
clinicopathological variables in CRC
To study the potential role of OTUB1 in CRC, we first
used IHC staining to analyze the expression of OTUB1
protein in 260 CRC patients who received tumor resection
at the Sun Yat-sen University Cancer Center between
January 1999 and December 2005. The characteristics
of the patients are summarized in Table 1. OTUB1
staining was localized to the cytoplasm. The staining was
scored based on the intensity of the staining (4 degrees,
Additional file 1: Figure S1) and the proportion of the
tumor staining positivity (as described in the Methods).
Compared to paired adjacent normal mucosal tissues, the
expression of OTUB1 was dramatically higher in tumor
tissues (Figure 1A and B, P <0.01). High OTUB1 expres-
sion was detected in 137 tumor tissues (52.7%), and low
OTUB1 expression was observed in 123 tumor samples
(47.3%, Table 1).
We next analyzed the relationship between clinico-
pathological features and the expression level of OTUB1.
The results revealed that the expression level of OTUB1
was significantly associated with tumor invasive depth
(P =0.001), lymph node status (P =0.015), distant me-
tastasis (P =0.013), and AJCC/TNM stage (P =0.003).
A high level of OTUB1 expression indicated a greater
depth of tumor invasion, the presence of lymph node
and distant metastasis. No other significant correlations
were observed between the OTUB1 expression level and
age, gender, tumor location, tumor size, chemotherapy, or
preoperative carcinoembryonic antigen (CEA) expression
level (Table 1). Chemotherapy is an important therapy for
stage III and IV colorectal cancer patients. We also ana-
lyzed the relationship between chemotherapy and the
expression level of OTUB1 per stage. As shown in
Additional file 2: Table S1, There was no statistical
significance.OTUB1 overexpression is associated with poor prognosis
in CRC
To assess the clinical significance of OTUB1 overexpres-
sion in CRC, we analyzed the relationship between the ex-
pression level of OTUB1 and patient survival. As shown
in Figure 1C and D, OTUB1 expression was negatively as-
sociated with PFS (P <0.001, HR 2.157, 95% CI, 1.393-
3.341) and OS (P <0.001, HR 2.187, 95% CI, 1.421-3.387).
Figure 1 IHC staining for OTUB1 in 260 CRC tissues. (A) Representative images (100 and 400 ×magnification) of IHC staining for OTUB1 in
CRC tissues and paired adjacent normal mucosal tissues. The scale bar represents 50 μm. (B) Relative IHC staining for OTUB1 in CRC tissues and
adjacent normal mucosal tissues. (n = 260, **P <0.01). (C) and (D) Kaplan-Meier survival analysis of the correlation between OTUB1 expression and
PFS and OS.
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vs. 73.1%) were significantly lower in the OTUB1 high-
expression group than that in the low-expression group.
The subgroup analysis was executed. As shown in
Additional file 3: Figure S2, OTUB1 expression was
negatively associated with IV stage PFS (P <0.016, HRTable 2 Multivariate analysis for PFS and OS
Variable PFS
HR (95% CI)
Age (year,<65 vs ≥65) 1.29 (0.81-2.07)
Gender (male vs female) 0.77 (0.48-1.22)
Tumor location (colon vs rectum) 1.39 (0.88-2.07)
Tumor size (cm, <5 vs ≥5) 0.83 (0.48-1.43)
Tumor invasive depth (T1-2 vs T3-4) 0.82 (0.33-2.00)
Lymph node status (<1 vs ≥1) 2.35 (1.25-4.41)
Distant metastasis (No vs Yes) 7.89 (4.58-13.61)
Preoperative CAE (ng/mL, <5 vs ≥5) 1.45 (0.86-2.44)
Chemotherapy (Yes vs no) 1.55 (0.94-2.56)
OTUB1 (low vs high) 1.61 (1.01-2.59)
PFS progression-free survival, OS overall survival, HR hazard ratio, CI Confidence int
*Statistically significant P <0.05.2.097, 95% CI, 1.138-3.862) and OS (P <0.011, HR
2.189, 95% CI, 1.184-4.048). Furthermore, Cox propor-
tional hazards regressions indicated that OTUB1 expres-
sion served as an independent prognostic factor for PFS
(P =0.049, HR 1.61, 95% CI 1.01–2.59) and OS (P =0.019,
HR 1.77, 95% CI 1.10-2.86; Table 2).OS
p value HR (95% CI) p value
0. 284 1.31 (0.82-2.10) 0.256
0.269 0.82 (0.50-1.27) 0.340
0.161 1.36 (0.86-2.15) 0.184
0.498 0.85 (0.49-1.47) 0.553
0.658 0.77 (0.31-1.90) 0.567
0.008* 2.43 (1.30-4.59) 0.006*
<0.001* 9.41 (5.49-16.16) <0.001*
0.160 1.54 (0.92-2.56) 0.101
0.087 1.59 (0.96-2.62) 0.069
0.049* 1.77 (1.10-2.86) 0.019*
erval.
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cell lines
Because high OTUB1 expression in primary CRC tissues
is associated with lymph node status and distant metas-
tasis, we analyzed whether OTUB1 was highly expressed
in lymph node or metastatic tumor tissues. IHC was
used to assess the level of OTUB1 expression in 20
grouped samples, including paired adjacent normal mu-
cosal tissues, primary CRC tissues and lymph node or
distant metastatic tumor tissues (include 7 liver metasta-
sis, 2 pelvic metastasis and 1ovary metastasis); represen-
tative images are shown in Additional file 4: Figure S3A
and S3C. OTUB1 expression in lymph node metastatic
tumor tissues and primary CRC tissues was higher than
that in adjacent normal mucosal tissues (Additional file 4:
Figure S3B and Additional file 5: Table S2a). And OTUB1
expression in distant metastatic tumor tissues was dramat-
ically higher than that in adjacent normal mucosal tissues
or primary CRC tissues (Additional file 4: Figure S3D and
Additional file 5: Table S2b). These results indicated that
OTUB1 expression may be associated with CRC metasta-
sis. We therefore analyzed the effect of OTUB1 on the mi-
gration and invasion of CRC cells in vitro.
To investigate the function of OTUB1 in CRC, we exam-
ined the expression of OTUB1 in CRC tissues and cell
lines. The expression level of mRNA for OTUB1 was in-
creased in 24 CRC tissues compared to their paired normal
tissues (Figure 2A, P <0.01). The expression of OTUB1
protein was also higher in CRC tissues (Figure 2B). More-
over, the expression of OTUB1 at the mRNA and pro-
tein levels was remarkably higher in SW620, HT29 and
SW1116 cells compared to FHC cells, and the OTUB1
expression level in HCT116 and SW480 cells was slightly
higher than that in FHC cells (Figure 2C and D, P <0.01).
FHC cell is a normal colon epithelial; HCT116, SW1116
and DLD-1 cells derived from colon primary tumor tis-
sues of patients with colorectal cancer; COLO205 derived
from the metastatic site (ascites) of colorectal cancer
patient; SW480 derived from a patient with colorectal
adenocarcinoma, and SW620 derived from the lymph
node of the same patient. So OTUB1 was overex-
pressed in OTUB1low cell line SW480 and knocked
down in OTUB1high cell line SW620 to research the ef-
fect of OTUB1 to migration and invasion. After trans-
fecting SW480 cells with OTUB1 expression plasmid or
empty vector for 48 hours, we observed that OTUB1 pro-
tein was overexpressed in SW480-OTUB1 cells (Figure 2E).
Transwell assays showed that the migration and invasion
ability of OTUB1-overexpressing cells were enhanced
(Figure 2F, P <0.01). SiRNAs were also used to knockdown
the expression of OTUB1 in SW620 cells, and Western
blot analysis showed that OTUB1 was downregulated fol-
lowing siRNA treatment (Figure 2G).The results showed
that knockdown of OTUB1 significantly suppressed themigration and invasion of SW620 cells (Figure 2H, P <0.01).
In additional that we wanted to know whether OTUB1
affect the migration and invasion ability of another cells.
Like SW480 and SW620 cells, p53 of DLD-1 cells were mu-
tated, so DLD-1 cells were chose for the model cell. Similar
to SW480 cells, after transfecting DLD-1 cells with OTUB1
expression plasmid or empty vector for 48 hours, we
observed that OTUB1 protein was overexpressed in
DLD-1-OTUB1 cells (Additional file 6: Figure S4A)
and the migration and invasion ability was enhanced in
DLD-1-OTUB1 cells (Additional file 6: Figure S4B). To
investigate whether OTUB1 overexpression or down-
regulation affected colorectal cells proliferation ability,
OTUB1 was transfected in SW480 and DLD1 cells and
siRNA of OTUB1 was transfected in SW620 cells, then
the cell growth rate was detected by CCK-8. We found
OTUB1 did not affect the growth rate of SW480, SW620
and DLD-1 in 4 days (Additional file 7: Figure S5), so the
proliferation of cells did not affect the migration and
invasion.
OTUB1 facilitates epithelial-mesenchymal transition (EMT)
in CRC cell lines
Morphological changes were observed in SW480 cells
stably expressing OTUB1 (Figure 3A). In particular,
the morphology of vector-transfected SW480 cells was
similar to that of normal SW480 cells, while OTUB1-
overexpressing cells tended to demonstrate an elon-
gated spindle-like shape. EMT is an important factor
in cell invasion and morphological changes, so we next
evaluated whether EMT markers were altered in our
model. The expression of ZEB1, β-catenin, vimentin,
E-cadherin, and N-cadherin at the protein level was
analyzed by Western blot (Figure 3B). We found that the
expression of ZEB1, β-catenin, N-cadherin, and vimentin
was increased, whereas E-cadherin expression was de-
creased, in SW480-OTUB1 cells, and the opposite re-
sults were obtained when OTUB1 was knocked down
in SW620 cells. Another, the protein expression of vimen-
tin was increased and the protein expression of E-cadherin
was decreased in DLD-1-OTUB1 cells (Additional file 8:
Figure S6). Furthermore, we performed immunofluor-
escence analysis to analyze the protein expression of
β-catenin, vimentin, and E-cadherin in CRC cell lines
(Figure 3C), and these results were consistent with
those of the Western blot assays. We also evaluated in
the mRNA expression of TCF8/ZEB1, β-catenin, and
vimentin in SW480 and SW620 cells, and changes of
mRNA expression were consistent with that observed
at the protein level (Additional file 9: Figure S7).
β-catenin are important EMT factors that are regulated
by GSK3β, which is in turn regulated by the PI3K-AKT
signaling pathway. Therefore, we next asked whether the
PI3K-AKT-GSK3β signaling pathway was involved in the
Figure 2 OTUB1 is expressed in CRC tissues and cell lines and promotes migration and invasion. (A) The relative expression level of
OTUB1 was examined by real-time PCR in 24 CRC tissues (T) and their paired normal mucosal tissues (N). β-actin was used as an endogenous
control (**P <0.01). (B) OTUB1 expression at the protein level was detected by Western blot analysis in 5 pairs of CRC tissues and paired normal
mucosal tissues. β-actin was used as a loading control. The relative mRNA expression level of OTUB1 was examined by real-time PCR (C) and the
protein level was detected by Western blot analysis (D) in 7 CRC cell lines and 1 normal colon epithelial cell line (FHC). β-actin was used as
an endogenous control (**P <0.01). (E) SW480 cells were transfected with the OTUB1 expression plasmid or empty vector for 48 hours, and
the expression of OTUB1 at the protein level was examined by Western blot in the OTUB1 overexpression group (SW480-OTUB1) and the
control group (SW480-Control). (F) Representative images showing the migration and invasion of SW480-OTUB1 and SW480-Control cells
are shown. The number of tumor cells is quantified on the right. All data are expressed as the means of three independent experiments (**P <0.01).
(G) SW620 cells were transfected with siRNAs against OTUB1 for 48 hours, and the expression level of OTUB1 at the protein level was examined by
Western blot. Representative images showing migration and invasion and the quantitative analysis are shown in (H). The data represent the
means of three independent experiments, and the error bars represent the SD (**P <0.01).
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file 10: Figure S8A, the overexpression of OTUB1 in
SW480 cells decreased PTEN expression and increased
p-AKT and p-GSK3β (S9) levels. In contrast, the down-
regulation of OTUB1 in SW620 cells increased PTEN
expression and decreased p-AKT and p-GSK3β (S9)
levels. After treatment with LY294002, an inhibitor of
the PI3K-AKT signaling pathway, p-AKT and p-GSK3β
(S9) levels were decreased in SW480-OTUB1 cells
(Additional file 10: Figure S8B), but the expression ofE-cadherin, vimentin, and β-catenin was not changed.
Therefore, the expression of these EMT markers is not
regulated by GSK3β. β-catenin is a important factor in
WNT signaling path, so we wanted to know whether
OTUB1 affect the activity of WNT signaling path. As
shown in Additional file 11: Figure S9, the overexpression
of OTUB1 in SW480 and DLD-1 cells or downregulation
of OTUB1 in SW620 cells did not changed the protein ex-
pression level of TCF1, LEF1 and DVL2. So OTUB1 might
be not influence Wnt signaling in our models.
Figure 3 OTUB1 facilitates EMT in CRC cells. (A) Morphological change images after overexpressing OTUB1 in SW480. (B) After overexpressing
OTUB1 in SW480 cells or downregulating OTUB1 expression in SW620 cells, the protein levels of TCF8/ZEB1, E-cadherin, N-cadherin, β-catenin,
and vimentin were measured by Western blot. (C) Immunofluorescence was used to compare the expression levels and expression pattern of
E-cadherin, β-catenin, and vimentin between SW480-OTUB1 and SW480-Control cells or SW620-siOTUB1 and SW620-siNC cells.
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MAKP was regulated by OTUB1 [18], so we evaluated
whether activity of NF-κB and MAKP was changed in
our models. As shown in Additional file 12: Figure
S10, overexpressing OTUB1 in SW480 and DLD-1
cells or downregulating OTUB1 in SW620 cells did
not change the expression level of p-JNK, p-p38
(MAPK), p-ERK. So MAPK signal path might not play
the major roles in our models. Overexpressing OTUB1
in SW480 and DLD-1 cells did not change the expres-
sion level of NF-κB (p65), but it could promote nuclear
transference of NF-κB (p65) and activate p-IκBα, and
the opposite results were obtained when downregulat-
ing OTUB1 in SW620 cells. So the activity of NF-κBwas regulated by OTUB1 in our models (Additional
file 13: Figure S11).
Close association between E-cadherin and nuclear β-catenin
expression and OTUB1 expression in CRC tissues
Because OTUB1 was shown to regulate the expression
of E-cadherin, β-catenin, and vimentin in CRC cell lines, we
sought to determine whether E-cadherin, β-catenin, and
vimentin expression was associated with OTUB1 expression
in CRC tissues. IHC staining was used to analyze the rela-
tionship between the expression of OTUB1 and E-cadherin,
β-catenin, and vimentin in 40 CRC tissues; representative
images are shown in Figure 4A. E-cadherin expression was
negatively correlated with OTUB1 expression (Figure 4B (i),
Figure 4 The correlation between the expression of OTUB1 and E-cadherin, β-catenin, and vimentin in 40 CRC tissues. (A) Representative
IHC staining for OTUB1, E-cadherin, β-catenin, and vimentin is shown in two CRC tissues. The scale bar represents 50 μm. (B) A correlation was detected
between E-cadherin, β-catenin, vimentin, and OTUB1 expression by Pearson’s test in 40 CRC tissues. The correlations between E-cadherin expression and
OTUB1(i), nuclear β-catenin expression and OTUB1(ii), and membranous β-catenin expression and OTUB1(iii) are shown, as well as the correlations
between cytoplasmic β-catenin expression and OTUB1(iv) and tumorous stromal vimentin expression and OTUB1(v).
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detected in the nucleus, membrane, and cytoplasm of CRC
tissues. Nuclear β-catenin expression was positively
correlated with OTUB1 expression (Figure 4B (ii), r =
0.553, P <0.001). Membranous and cytoplasmic β-catenin
expression was not associated with OTUB1 expression
(Figure 4B (iii) and (iv)). In CRC tissues, vimentin was
expressed in the tumor stroma but was not detected in
cancer cells (Figure 4A). The expression of tumorousstromal vimentin was not correlated with OTUB1 expres-
sion (Figure 4B (v)).
Ectopic overexpression of OTUB1 increases the liver
metastatic potential of CRC cells in vivo
To investigate whether OTUB1 increases the metastatic
capacity of CRC cells in vivo, two nude mouse models of
liver metastasis were used. SW480-OTUB1 cells, which
stably express OTUB1, and SW480-Control cells were
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the mice were sacrificed. Images showing representative
livers with general metastasis were presented in Figure 5A,
and images of HE and IHC staining were shown in
Figure 5B. In contrast to the SW480-Control group,
the expression of OTUB1 was increased and the majority
of mice presented liver metastases in the SW480-OTUB1
group, and the number of metastatic nodules in the
SW480-OTUB1 group was higher than that observed in
the control group (Figure 5C, P <0.01).
In another liver metastasis model, SW480-OTUB1 and
SW480-Control cells were injected into the tail veins of
nude mice. Images showing representative livers with
general metastasis and HE and IHC staining are pre-
sented in Additional file 14: Figure S12A and S12B. Simi-
lar to the spleen injection model, the SW480-OTUB1
group demonstrated more pronounced liver metastasis
(Additional file 14: Figure S12C, P <0.05).
Discussion
In this study, we observed that the expression of OTUB1
in CRC tissues was dramatically higher than that in
paired normal mucosal tissues (Figure 1A and 1B) and
that OTUB1 expression was associated with lymph node
status and distant metastasis (Table 1). In particular,
high OTUB1 expression in cancer tissues indicated a
poorer PFS and OS (Figure 1C and 1D). The subgroup
analysis, OTUB1 expression was negatively associated
with PFS and OS in stage IV and not associated with stage
I, II, III (Additional file 3: Figure S2). There may be a var-
iety of mechanisms involved in OTUB1 promoting the
metastasis of colorectal cancer. In our reports, OTUB1
could regulate the expression of EMT markers (Figure 3),
PI3K-AKT-GSK3β signaling pathway (Additional file 10:Figure 5 Overexpression of OTUB1 promotes CRC liver metastasis in
spleens of nude mice. Ten weeks later, the mice were sacrificed. (A) Repr
spleen. The metastatic nodules are indicated with red arrows. (B) Repres
livers are shown. The metastatic nodules are indicated with red arrows.
(C) (n = 8; **P <0.01).Figure S8B) and nuclear transference of NF-κB (p65)
(Additional file 13: Figure S11). In CRC, NF-κB (p65) was
significantly higher in primary tumor and liver metastases
than normal mucosa. Activation of NF-κB (p65) as mea-
sured by nuclear expression is strongly associated with
survival and as a prognostic factor in stage IV patients of
CRC [22]. So OTUB1 expression may be negatively asso-
ciated with PFS and OS in stage IV patients in a small spe-
cimen. OTUB1 expression was not associated with stage
II, III patients in the data, but the number of per tumor
stage is small and our results indicated that E-cadherin ex-
pression was negatively correlated with OTUB1 expres-
sion and nuclear β-catenin expression was positively
correlated with OTUB1 expression in colorectal tissues.
E-cadherin and nuclear β-catenin are important factors in
EMT for CRCs. So we supposed that increasing the num-
ber of patients may show the association between OTUB1
expression and stage II and III patients. We will increase
the number of patients to research the association be-
tween the expression of OTUB1 and per tumor stage in
the future. Cox proportional hazards analysis revealed that
OTUB1 served as an independent prognostic factor for
CRC (Table 2). Chemotherapy is an important treatment
for patients with advanced cancer. In our report, chemo-
therapy was not an independent prognostic factor for
CRCs and partial of stage I patients treated with chemo-
therapy and relatively some stage IV CRC patients did not
treat with chemotherapy. The 260 CRC patients in our
study were chose between January 1999 and December
2005. And we found that the stage I patients treated with
chemotherapy gathered from 1999 to 2003. At that time,
the standard treatment of colorectal cancer was not ac-
cepted by all doctors in china, so partial of stage I patients
were treated with chemotherapy because surgeons worriedvivo. SW480-OTUB1 or SW480-Control cells were injected into the
esentative images of general livers after tumor cell injection into the
entative results for HE and IHC staining of metastatic nodules in the
The scale bar represents 50 μm. The statistical analyses are shown in
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tients rejected chemotherapy because they had false beliefs
to chemotherapy and did not consider chemotherapy was
beneficial for them. But now the standard treatment of
colorectal cancer on the basis of NCCN guideline was
used in cancer centers in china, such as the Sun Yat-sen
University Cancer Center.
More than 25% CRC patients will develop metastasis
after diagnosis, and because metastasis is the major
cause of death in CRC patients, the identification of
prognostic factors for predicting the risk of metastasis is
important for improvements in CRC clinical treatment.
CEA expression is an established prognostic indicator of
postoperative recurrence and metastasis, but this meas-
urement only provides a sensitivity of 34%, a specificity
of 84%, and a median lead time of 4.5 months from de-
tection to clinical recurrence [23]. Therefore, other
sensitive factors that can predict the metastasis and re-
currence of CRC are urgently needed. We found that
the expression level of OTUB1 was associated with
lymph node status, distant metastasis, and survival in
CRC, which suggests that in combination with other
markers, OTUB1 may serve as a biomarker of metasta-
sis and a prognostic factor to estimate the prognosis of
CRC. However, this study only examined one set of
cancer samples from a single clinical center; in the fu-
ture, we hope to increase the sample size and draw pa-
tients from multiple clinical research centers to verify
these results.
OTUB1 is an important factor for the stabilization and
activation of p53 [19], and the p53 gene is believed to be
deleted or mutated in 65% to 85% of CRC patients [20].
In this study, we used SW480 SW620 and DLD-1cells
with mutated p53 as models to study the functions of
OTUB1 in CRC. We found that overexpressing OTUB1
in SW480, DLD-1 cells or downregulating OTUB1 in
SW620 cells did not influence p53 expression (data not
shown). So another mechanism might be involved in the
metastasis regulation of OTUB1 in CRC. By facilitating
the expression of EMT markers (Figure 3 and Figure 4),
OTUB1 promoted CRC cell migration and invasion
in vitro (Figure 2). We also used an intrasplenic injec-
tion mouse model that mimics liver metastasis through
the hepatic portal vein and a tail vein injection model
that mimics liver metastasis from the systemic circulation.
These results revealed that OTUB1 promoted CRC cell
liver metastasis in vivo (Figure 5 and Additional file 14:
Figure S12). EMT is crucial for the dissemination and inva-
sion of cancers with epithelial origins [24]. The most im-
portant event in EMT is the loss of E-cadherin at the cell
membrane surface, which is a key hallmark of EMT
[25,26]. The loss of E-cadherin has been detected in vari-
ous tumors, such as breast carcinoma [27,28], gastric
cancer [29], head and neck cancer [30], lung cancer[31], esophageal cancer [32], and CRC [33,34]. Previ-
ous studies have further shown that the expression of
E-cadherin is decreased in colon cancer tissues and in
invasive CRC compared to adjacent normal mucosa
[35,36]. The loss of E-cadherin expression results in
EMT and cancer metastasis [37], and E-cadherin has
been shown to be inhibited by several EMT regulators,
including SNAIL, TWIST, ZEB1, and ZEB2. The tran-
scription factor ZEB1, a zinc finger protein encoded by
the TCF8 gene, has been shown to act as a transcriptional
repressor of E-cadherin [38]. In our reports, E-cadherin
expression was regulated by OTUB1 in CRC cell lines,
and the level of E-cadherin protein expression was nega-
tively correlated with OTUB1 in CRC tissues (Figure 3
and Figure 4). The expression of ZEB1 was consistent with
alterations in OTUB1 expression (i.e., overexpression in
SW480 cells or downregulation in SW620 cells), whereas
the mRNA and protein expression of E-cadherin was
in contrast to that of OTUB1. Together, these results
suggest that alterations in E-cadherin expression driven by
OTUB1 may be regulated by ZEB1.
Vimentin, a constituent of the intermediate filament
family of proteins, is regarded as a canonical marker of
EMT. The loss of vimentin has been investigated in
many tumor types, including prostate cancer, gastric
cancer, lung cancer, malignant melanoma, central ner-
vous system tumors, and CRC [39]. OTUB1 expression
in the tumor stroma may also reflect a higher malignant
potential of CRC [40,41]. In present study, vimentin was
not expressed in cancer cells but was expressed in tumor
stromal cells in CRC tissues, which is in accordance
with previous studies. We found that OTUB1 regulated
vimentin in CRC cell lines, although vimentin expression
in the tumor stromal cells of CRC tissues was not corre-
lated with OTUB1 expression. The reason for this finding
may be that the tumor cells of CRC tissues consist of epi-
thelial cells, whereas most of the tumor stromal cells are
mesenchymal cells. Vimentin expression is regulated by
many factors, such as microRNA-138, which inhibits mi-
gration and invasion by directly targeting vimentin in
renal cell carcinoma. In addition, the vimentin gene is also
highly methylated in CRC tissues [41,42]. Here, we ob-
served that OTUB1 is a new regulator of vimentin in CRC
cell lines.
β-catenin plays a dual role in epithelial cells; this pro-
tein is an important component of the adherens junc-
tions linking E-cadherin at the plasma membrane and
also acts as the main effector of the canonical WNT
signaling cascade in the nucleus [43]. In the nucleus,
β-catenin acts as a transcription factor in a complex
with the TCF/LEF family of transcription factors [44]
and actives downstream genes such as c-myc and cyc-
lin D1. Nuclear β-catenin expression increases from
early colorectal adenomas to adenocarcinomas [45],
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node metastasis and poor survival [46]. In our analysis
of CRC tissues, the nuclear expression of β-catenin
was correlated with OTUB1 expression. This result is
consistent with the finding that high OTUB1 expression is
associated with poor survival in CRC patients. Moreover,
the mRNA and protein expression of β-catenin was found
to be regulated by OTUB1, and the changes in β-catenin
protein were mostly restricted to the cytoplasm of
CRC cell lines (Figure 3C). GSK-3β phosphorylates the
N-terminal domain of β-catenin, resulting in the ubiqui-
tylation and degradation of β-catenin [47]. In SW480 cells,
GSK3β does not degrade β-catenin due to a lack of APC
[48]. At the same time, a high level of N-cadherin expres-
sion blocks β-catenin entry into the nucleus [49], so the
changes in β-catenin mediated by OTUB1 were observed
in the cytoplasm in our model, which might be the rea-
son why TCF1, LEF1 were not activated in our models
(Additional file 11: Figure S9). In summary, OTUB1
acts as a multifunctional factor to regulate the expres-
sion of E-cadherin, β-catenin, and vimentin during the
EMT of CRC cells.
Conclusions
Together, our findings demonstrate that OTUB1 pro-
motes the migration, invasion, and metastasis of CRC
cells in vitro and in vivo and acts as a potential metasta-
sis marker and prognostic factor in CRC. Therefore, it is
intriguing to speculate that OTUB1 may be used as a
biomarker to predict CRC metastasis and may provide
new strategies for treatment.
Methods
Immunohistochemical (IHC) staining
CRC tissues were collected at the Sun Yat-sen University
Cancer Center. Formalin-fixed, paraffin-embedded cancer
tissues were sectioned to a thickness of 4 μm. After routine
deparaffinization, rehydration, blocking with hydrogen per-
oxide, and tissue antigen retrieval with a microwave, the
samples were incubated with rabbit anti-OTUB1 polyclonal
antibody (ab103995, 1:1,000, Abcam, Cambridge, MA),
rabbit anti-β-catenin antibody (#8480, 1:200, Cell Signal-
ing Technology), mouse anti-E-cadherin antibody (#3195,
1:200, Cell Signaling Technology), or rabbit anti-vimentin
antibody (#5741, 1:200, Cell Signaling Technology) over-
night at 4°C. The slides were stained with secondary
antibody and diaminobenzidine tetrahydrochloride (DAKO,
Carpinteria, CA) and then counterstained with hematoxylin.
The stained slides were evaluated independently by 2 inves-
tigators who were unaware of the clinical parameters. The
IHC staining was evaluated as described by Abubaker and
Cai [50,51]. The IHC staining intensity was scored from 0-3
(I0, I1-3): negative staining (0), weak staining (1), moderate
staining (2), and strong staining (3). The proportion of thetumor staining for that intensity was recorded as 5% incre-
ments from a range of 0–100 (P0, P1–3). The final H score
(range 0–300) was calculated for each intensity and propor-
tion of area stained (H score = I1XP1 + I2XP2 + I3XP3). ROC
curve analysis was used to determine cutoff value for
OTUB1 high expression or OTUB1 low expression. The
score that was closest to the point with both maximum
sensitivity and specificity was selected as the cutoff
value (H score =175).
Cell lines and culture conditions
The human embryonic kidney cell line HEK-293 T, the
human colon cancer cell lines SW480, SW620, HCT116,
HT29, DLD-1, SW1116, and COLO205; and the normal
colon epithelium cell line FHC were obtained from the
American Type Culture Collection. All CRC cell lines and
HEK-293 T were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS). FHC cells were cultured in DMEM:F12
medium (containing 10 ng/ml cholera toxin, 0.005 mg/ml
insulin, 0.005 mg/ml transferrin, and 100 ng/ml hydrocor-
tisone) supplemented with 10% FBS. All cells were main-
tained in a humidified 5% CO2 atmosphere at 37°C.
Real-time PCR analysis ofthe expression of OTUB1
Total RNA was extracted from CRC cell lines and tis-
sues using Trizol (Invitrogen). Two micrograms of total
RNA was used to synthesize complimentary DNA with
M-MLV reverse transcriptase (Promega, Madison, WI).
For quantitative real-time PCR (qPCR), cDNA products
were amplified using a SYBR Green PCR Kit (Invitrogen).
Quantification was performed using the Stratagene
MX300P sequence detection system (Stratagene). OTUB1
expression values were normalized to those of the house-
keeping gene β-actin and calculated using the comparative
CT method (2-ΔΔCT). The primer sequences are provided
in Additional file 15: Table S3.
Cell transfection
To generate the pcDNA3.1-OTUB1 plasmid, full-length
human OTUB1 (which was cloned using the primers
forward: 5’-ATTGGATCCACCATGGCGGCGGAGGAA
CCT-3’ and reverse: 5’- ATGCTCGAGCTATTTGTAG
AGGATATCGTA-3’) was released by BamH I and Xho I
digestion and inserted into pcDNA3.1. In addition, two
siRNAs were designed and synthesized by GenePharma
Company to knockdown the expression of OTUB1. The
siRNA sequences were as follows: #1, 5’-UUAACTGU
CUGGCCUAUGATT-3’ and #2, 5’-CCAUGUGCAAG
GAGAGCGATT-3’. A negative siRNA control with the
sequence 5’-UUCUCCGAACGUGUCACGUTT-3’ was
also used. To perform transient transfections, 4×105
SW480, DLD-1 or SW620 cells were seeded in 6-well
plates. Twenty-four hours later, the cells were transfected
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fectamine 2000 (Invitrogen, Carlsbad, CA) according to
the manufacturer’s protocol. After 48 hours, the cells were
collected for qPCR, western blotting, migration, invasion,
and immunofluorescence assays.
Western blot analysis
Total cellular proteins were extracted in lysis buffer (1%
NP-40, 0.1% sodium dodecyl sulfate, pH 7.3, 50 mM
Tris, and 150 mM NaCl) with protease inhibitors (Roche)
and phosphatase inhibitors (KeyGEN Biotech) for 30 min
on ice and centrifuged at 15,000 rpm at 4°C. Nuclear and
Cytoplasmic Protein Extraction kIt (KeyGEN Biotech) was
used to separate the nuclear and cytoplasmic protein ac-
cording to the manufacturer’s protocol. Western blots were
carried out as previously described [52]. The primary anti-
bodies used included anti-TCF8/ZEB1, anti-β-catenin,
anti-p-GSK3β (S9), anti-GSK3β, anti-AKT, anti-p-AKT,
anti-PTEN, anti-E-cadherin, anti-N-cadherin, anti-vimentin,
anti-TCF1, anti-LEF1, anti-DVL2, anti-p-JNK, anti-p-ERK,
anti-p-p38 (MAPK), anti-NF-κB (p65) , p-IκBα (all 1:1,000;
Cell Signaling Technology), anti-OTUB1 (1:1,000; Abcam,
Cambridge, MA), anti-GAPDH (1:2,000; Santa Cruz
Biotechnology, Santa Cruz, CA), and anti-β-actin (1:2,000;
Santa Cruz Biotechnology, Santa Cruz, CA), anti-Histone
H3 (1:2,000; Santa Cruz Biotechnology, Santa Cruz, CA).
Migration and Invasion assays
To study the effect of OTUB1 on the migration and inva-
sion of colorectal cells, 4×105 SW480, DLD-1 or SW620
cells were seeded in 6-well plates. Twenty-four hours later,
the cells were transfected with 4 μg of OTUB1 plasmid
DNA or 100 nM siRNA using Lipofectamine 2000 accord-
ing to the manufacturer’s protocol. After transfection with
plasmid or siRNA for 24 hours, 1×105 cells in serum-free
medium were seeded into the Boyden chamber without
Matrigel (8-μm pore; BD Falcon, San Jose, CA) for migra-
tion or the chamber with Matrigel (8-μm pore; BD Falcon)
for invasion. Then the chambers were put in 24-well
plates with medium with 10% FBS. The chambers were in-
cubated for 24 hours at 37°C with 5% CO2. The cells on
the underside of filter membrane were fixed in ethanol
and stained with crystal violet. The cells were counted
under a microscope.
Measurement of cell proliferation
After transfection with plasmid or siRNA for 6 hours,
3×103 SW480, SW620 and DLD-1 cells were seeded into
96-well culture plates. Cell proliferation was determined
using Cell Counting Kit-8 (CCK-8, Dojindo, Kumamoto,
Japan) at 0, 24, 48, 72, 96 hours. 10 μL of CCK-8 solu-
tion were added to the 90 μL medium and incubated for
2 h in an incubator with 5% CO2 atmosphere at 37°C.The absorbance was measured by a microplate reader at
450 nm.
Lentivirus packaging and transduction
We used a lentivirus system (System Biosciences, Inc.) to
stably express OTUB1 in SW480 cells. OTUB1 cDNA
was cloned and inserted into the pCDH- CMV-MCS-EF1
vector. 293 T cells were transfected with pCDH-OTUB1
or pCHD vector and the package plasmids according to
the manufacturer’s instructions. Virus particles were har-
vested 48 hours after transfection. SW480 cells were in-
fected with virus particles and selected by flow cytometry
according to green fluorescence. Western blotting was
used to detect OTUB1 expression.
Immunofluorescence
A total of 4×105 cells were seeded into glass-bottom cell cul-
ture dishes (NEST Biotechnology Co., LTD). After 24 hours,
the cells were fixed in 4% paraformaldehyde, permeabilized
using 0.5% Triton X-100, and blocked with 3% bovine serum
albumin. The cells were incubated with a primary anti-E-
cadherin (1:100, Cell Signaling Technology), anti-β-catenin
(1:200, Cell Signaling Technology), or anti-vimentin (1:200,
Cell Signaling Technology) antibody overnight at 4°C,
followed by incubation with a Alexa fluor-594-conjugated
secondary antibody (Invitrogen). The samples were
co-stained with 4',6-diamidino-2-phenylindole (DAPI)
and examined by confocal microscopy.
Animal model
Female 4- to 5-week-old BABL/c nude mice were
purchased from the Experimental Animal Center of
Guangdong Province (Guangzhou, China). All animal
studies were conducted in accordance with the current
Chinese regulations and standards regarding the use of
laboratory animals, and all animal procedures were ap-
proved by the Sun Yat-sen University Institutional
Animal Care and Use Committee.
The mice were randomly allocated into four groups (n = 8)
in two experiments to study liver metastasis. Two groups re-
ceived spleen injection, and the others received tail vein in-
jection. The experimental procedure has been described
previously [53]. For the spleen injection experiment, the
mice were anesthetized with isoflurane and laparotomized to
pull the spleen out of the abdominal cavity. A total of 1×106
cells (SW480-OTUB1 or SW480-Control) in 20 μl of
phosphate-buffered saline (PBS) were slowly injected into
the spleen using an insulin syringe. The spleen was then re-
placed in the abdomen, and the abdominal wall was sutured.
Ten weeks later, the mice were euthanized, and the livers
were removed for pathological examination. For the tail vein
injection experiment, 1.2×106 cells in 100 μl of PBS were
injected into the tail vein of mice using an insulin syringe.
After ten weeks, the mice were euthanized, and the livers
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paraffin-embedded liver tissues were sectioned at a thickness
of 5 μm at 10 different planes to cover the entire liver.
The sections were stained with hematoxylin and eosin
(HE) and IHC, and the metastatic nodules were counted
by microscopy [53,54].Statistical analysis
Two-tailed χ2 tests were used to assess the significant
associations between OTUB1 expression and clinico-
pathological parameters. Survival analysis was calculated
using the Kaplan-Meier method. The log-rank test was
used to compare survival curves. A Cox proportional
hazards model was used to calculate the multivariate
hazard ratios for clinicopathological parameters and the
OTUB1 expression level with respect to overall survival
(OS) and progression-free survival (PFS). Pearson’s test
was applied for the correlation analysis. The significance
of the in vitro and in vivo data was determined using the
two-tailed t-test. P-values <0.05 were considered statisti-
cally significant. Statistical analyses were performed using
the SPSS software package (SPSS Standard version 17.0,
SPSS Inc., Chicago, IL).Additional file
Additional file 1: Figure S1. Representative images
(200×magnification) of IHC staining for OTUB1 in CRC tissues. OTUB1
protein expression was scored from 0 to 3. A score of 0 represents
negative staining (A), a score of 1 indicates weak positive staining (B), a score
of 2 indicates moderate positive staining (C), and a score of 3 represents
strong positive staining (D). The scale bar represents 50 μm.
Additional file 2: Table S1. Chemotherapy of per stage correlation
with OTUB1 expression.
Additional file 3: Figure S2. Kaplan-Meier survival analysis of the
correlation between OTUB1 expression and PFS and OS of per stage. (A)
Kaplan-Meier method was used to analyze the correlation between
OTUB1 expression and PFS and OS of stage I CRC. (B) Kaplan-Meier
method was used to analyze the correlation between OTUB1 expression
and PFS and OS of stage II CRC. (C) Kaplan-Meier method was used to analyze
the correlation between OTUB1 expression and PFS and OS of stage III CRC.
(D) Kaplan-Meier method was used to analyze the correlation between
OTUB1 expression and PFS and OS of stage IV CRC.
Additional file 4: Figure S3. OTUB1 are expressed in 10 paired
adjacent normal mucosal tissues, primary tumor tissues and lymph node
metastatic tissues or distant metastatic tissues. (A) Representative images
of adjacent normal mucosal tissues, primary tumor tissues and lymph node
metastatic tumor tissues from one patient sample are shown. (B) Relative
IHC staining for OTUB1 in adjacent normal mucosal tissues, primary
tumor tissues, and lymph node metastatic tumor tissues is shown
(n=10, **P < 0.01). (C) Representative images of adjacent normal
mucosal tissues, primary tumor tissues, and distant metastatic tumor
tissues from one patient sample are shown. (D) Relative IHC staining
for OTUB1 in adjacent normal mucosal tissues, primary tumor tissues,
and distant metastatic tissues is shown (n=10, **P < 0.01, * P < 0.05).
Additional file 5: Table S2a. The H scores of OTUB1 expression in
normal mucosal tissues, primary tumor tissues and lymph node
metastatic tumor tissues in 10 paired tissues. And Table S2b The H
scores of OTUB1 expression in normal mucosal tissues, primary tumor
tissues and distant metastatic tumor tissues in 10 paired tissues.Additional file 6: Figure S4. OTUB1 promotes DLD-1 cells migration
and invasion. DLD-1 cells were transfected with the OTUB1 expression
plasmid or empty vector for 48 hours, and the expression of OTUB1 at
the protein level was examined by Western blot in the OTUB1 overexpression
group (DLD-1-OTUB1) and the control group (DLD-1-Control) (A).
Representative images showing the migration and invasion of DLD-1-OTUB1
and DLD-1-Control cells are shown (B). The number of tumor cells is quantified
on the right. All data are expressed as the means of three independent
experiments (**P < 0.01, *P < 0.05).
Additional file 7: Figure S5. OTUB1 does not affect the growth of
SW480, SW620 and DLD-1. After transfecting SW480, DLD-1 cells with
OTUB1 expression plasmid or empty vector or transfecting SW620 cells
with siRNA of OTUB1 or NC, the cell growth rate were detected at 0, 24,
48, 72, 96 hours. A-C represented SW480, SW620 and DLD-1 cells respectively.
Additional file 8: Figure S6. OTUB1 facilitates EMT markers in DLD-1
cells. After overexpressing OTUB1 in DLD-1 cells, the protein levels of
E-cadherin, β-catenin, and vimentin were measured by Western blot in
the OTUB1 overexpression group (DLD-1-OTUB1) and the control
group (DLD-1-Control).
Additional file 9: Figure S7. The mRNA expression levels of EMT
markers are affected by OTUB1 in CRC cell lines. OTUB1 was
overexpressed or downregulated in SW480 cells (A) or SW620 cells (B),
respectively, and the mRNA expression level of TCF8/ZEB1, E-cadherin,
β-catenin, and vimentin was detected by q-PCR. β-actin was used as
an endogenous control (**P < 0.01, * P < 0.05).
Additional file 10: Figure S8. OTUB1 regulates the PI3K-AKT-GSK3β
signaling pathway. After overexpressing OTUB1 in SW480 cells or
knocking down OTUB1 in SW620 cells, PTEN, p-AKT, AKT, p-GSK3β (S9),
and GSK3β were measured by Western blot (A). After LY294002 or
DMSO treatment for 2 hours, p-AKT, AKT, p-GSK3β (S9), GSK3β, E-cadherin,
β-catenin and vimentin were measured in SW480-OTUB1 and SW480-Control
cells by western blot (B).
Additional file 11: Figure S9. OTUB1 does not affect expression of
TCF1, LEF1 and DVL2. After overexpressing OTUB1 in SW480 or DLD-1
cells or knocking down OTUB1 in SW620 cells, the protein expression
level of TCF1, LEF1 and DVL2 were measured by Western blot.
Additional file 12: Figure S10. OTUB1 does not affect MAKP signaling
path. After overexpressing OTUB1 in SW480 or DLD-1 cells or knocking
down OTUB1 in SW620 cells, the protein expression level of p-JNK, p-ERK,
p-p38 (MAPK) were measured by Western blot.
Additional file 13: Figure S11. OTUB1 regulate NF-κB signaling path.
After overexpressing OTUB1 in SW480 or DLD-1 cells or knocking down
OTUB1 in SW620 cells, cell, cytoplasmic and nuclear lysate was achieved.
The protein expression level of NF-κB and p-IκBα were measured by
Western blot.
Additional file 14: Figure S12. Overexpression of OTUB1 promotes
CRC liver metastasis in vivo. SW480-OTUB1 or SW480-Control cells were
injected into the tail veins of nude mice. Ten weeks later, the mice were
sacrificed. (A) Representative figures of general livers are shown, and
metastatic nodules are indicated with red arrows. (B) Representative results
for HE and IHC staining of metastatic nodules in the livers are shown. The
metastatic nodules are indicated with red arrows. The scale bar represents
50 μm. The statistical analysis is shown in (C) (n=8; * P < 0.05).
Additional file 15: Table S3. Primer sequences in qPCR analysis.Abbreviations
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